Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum SQI Diagnostics Inc V.SQD.H

SQI Diagnostics Inc. is a Canada-based company that is focused on lung health. The Company is engaged in the development and manufacturing of respiratory health and precision medicine tests that run on its fully automated systems. Its clinical solutions include Rapid Acute Lung Injury Diagnostic (RALI-Dx), lung transplant diagnostics, COVID-19 testing and surveillance testing solutions. Its... see more

TSXV:SQD.H - Post Discussion

SQI Diagnostics Inc > Couple important reads to connect dots. SQI is Key!
View:
Post by FactFinder1994 on Jun 05, 2023 2:26pm

Couple important reads to connect dots. SQI is Key!

TORONTO METHOD

Our clinical trial is based on the Toronto EVLP protocol which is the most widely used and most referenced method for EVLP. In this method, protective perfusion and ventilation strategies are used to gather additional information about the functionality of the lungs.

Lung Bioengineering | Centralized Ex Vivo Lung PerfusionLung Bioengineeringhttps://www.lungbioengineering.com

Advanced rapid diagnostic profiling will be required to bring the precision medicine concept to the bedside of donor organ management. Is this lung okay to go straight to transplant, or do you need to repair it? If you do need to repair it, diagnose the problem, define your prescription of repair, repair it, confirm that your lung is repaired, and transport it to your recipient to implant an organ that is a known product with a predicable good outcome.

A whole industry is developing around machines to perfuse organs, diagnostics to improve precision in decision making, and service providers to manage the organs. Furthermore, we cannot continue to build whole operating rooms to manage one organ at a time. Devices are being developed to automate these complex processes for each or- gan (lung, liver, kidney, heart), so that an organ perfusion specialist can monitor and treat multiple organs at the same time. Important health economic analyses should include examination of the combined cost effectiveness of EVLP in the context of the value of increased availability of donor lungs—which will save more lives and increased access to transplantation, and shorten the duration of care required for advanced end stage lung disease patients, com- bined with the benefit gained from more efficient organ management and transportation and ultimately from trans- plantation of organs with better and more predictable improved short and long term outcomes.

The field of transplantation has changed. We have an un- precedented opportunity to use more organs and improve the outcomes of transplantation. The clinical translation of EVLP technology has demonstrated the way forward for the development of a redesigned transplant ecosystem. Organs will be retrieved from a donor by a regional surgical retrieval team (or in a donor-management center), trans- ported by drone to an organ repair center, treated and optimized for transplantation, and transported to the recip- ient for elective transplantation. This is fact, not fiction:

clinical organ repair centers are already up and running. Furthermore, the components are coming together to re- engineer the transplant ecosystem to create a much more efficient, cost-effective, and sustainable delivery strategy for clinical organ transplantation.

Human organ repair centers: Fact or fiction?JTCVS Openhttps://www.jtcvsopen.org › article › pdf
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities